Tibetan Herbal Complex Reverses Cellular Aging via P21/P53/SIRT1 Pathway
A four-herb Tibetan formula cuts senescent cardiomyocytes nearly in half and boosts antioxidant defenses in zebrafish, targeting a core aging signaling axis.
Résumé
Researchers tested SBT, a Tibetan multi-herb formula containing Solms-laubachia eurycarpa, Bergenia purpurascens, Laccifer lacca, and Glycyrrhiza uralensis, in two aging models. In D-galactose-stressed H9c2 cardiomyocytes, SBT restored cell viability from 52% to 85% and cut senescent cell burden from 41% to 20%. Molecularly, it simultaneously reduced pro-senescence proteins P53 and P21 while boosting the longevity deacetylase SIRT1—a bidirectional regulatory maneuver rarely achieved by single compounds. In H2O2-exposed zebrafish larvae, SBT improved survival and heart rate, raised SOD, CAT, and glutathione levels, and lowered oxidative damage marker MDA. The formula also suppressed apoptosis in both models. These converging results across cell and whole-organism systems suggest SBT warrants further investigation as a natural senotherapeutic.
Résumé détaillé
Cellular senescence—the irreversible exit from the cell cycle—drives aging and fuels diseases from heart failure to neurodegeneration. The P53→P21 axis enforces this arrest while SIRT1, an NAD⁺-dependent deacetylase, counteracts it by deacetylating and inhibiting P53. Existing senotherapeutics like rapamycin carry substantial side-effect burdens, motivating the search for safer multi-target botanical alternatives.
This study examined SBT (Srolo Bzhtang), a defined four-herb Tibetan formulation rich in flavonoids (liquiritin, isoliquiritin), phenolic acids (bergenin), tannins, and polysaccharides. Two complementary aging models were used: D-galactose-induced senescence in rat H9c2 cardiomyocytes and H2O2-induced accelerated aging in zebrafish larvae, providing both cellular mechanistic detail and whole-organism physiological validation.
In cardiomyocytes, GAL treatment collapsed viability to 52% and drove 41.2% of cells to SA-β-gal positivity—a canonical senescence marker. SBT restored viability to 85% and halved the senescent fraction to 20%, both at p<0.0001. Fluorescence imaging confirmed marked ROS attenuation. TUNEL staining showed reduced apoptosis. Western blotting revealed the key mechanistic finding: SBT coordinately downregulated both P53 and P21 proteins while upregulating SIRT1—a bidirectional modulation of the senescence axis that single-molecule drugs rarely achieve simultaneously. Bcl-2/Bax gene expression shifted anti-apoptotically, and qPCR confirmed transcriptional changes in senescence and inflammation markers consistent with protein data.
In zebrafish, H2O2 exposure impaired survival and heart rate; SBT reversed both endpoints. Antioxidant enzyme activities (SOD, CAT) rose, glutathione levels increased, and the lipid peroxidation marker MDA fell. Acridine orange staining of larval heart tissue confirmed reduced apoptotic signaling, and SA-β-gal staining confirmed reduced organismal senescence burden. Western blots in zebrafish recapitulated the P53/P21 downregulation and SIRT1 upregulation observed in cardiomyocytes, strengthening the mechanistic case.
The dual-model concordance is notable: a cell-culture system identified the molecular target (P21/P53/SIRT1 axis plus Bcl-2/Bax), while zebrafish provided physiologically integrated confirmation including cardiac function and systemic antioxidant capacity. These findings position SBT as a multi-target senotherapeutic candidate, though substantial work remains before clinical translation.
Principales conclusions
- SBT restored D-galactose-damaged cardiomyocyte viability from 52% to 85% (p<0.0001).
- SA-β-gal-positive senescent cells dropped from 41.2% to 20% after SBT treatment.
- SBT simultaneously downregulated P53 and P21 while upregulating SIRT1, a bidirectional senescence axis effect.
- In zebrafish, SBT raised SOD, CAT, and GSH while cutting MDA and improving survival and heart rate.
- Anti-apoptotic Bcl-2/Bax ratio improved and apoptosis was reduced in both models.
Méthodologie
Dual-model design: D-galactose-induced senescence in rat H9c2 cardiomyocytes (CCK-8, SA-β-gal, TUNEL, ROS fluorescence, Western blot, qPCR) and H2O2-induced accelerated aging in zebrafish larvae (survival, heart rate, ROS, SOD/CAT/GSH/MDA assays, acridine orange staining, SA-β-gal, Western blot). Both models independently validated SBT's mechanistic targets.
Limites de l'étude
All experiments are preclinical (cell culture and zebrafish larvae), so human efficacy and safety remain unestablished. The active constituents responsible for the P21/P53/SIRT1 modulation were not individually identified, limiting mechanistic precision. Pharmacokinetic data, optimal dosing, and long-term toxicity in mammals are absent.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :